TICKERNOMICS Sign up
Last Update: 2024-03-28 02:12:56
Nanobiotix S.A. ( NBTX ) https://www.nanobiotix.com
6.15USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
France
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
NBTX
70.83%
SPY
32.74%
-58.85%
NBTX
SPY
92.93%
NBTX
0.00%
SPY
224.41%
NBTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
216.79
262.80
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.43
279.40
-3.71
-17.77
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-280.05
-617.56
0.00
Other Earnings and Cash Flow Stats:
Nanobiotix S.A. ( NBTX ) Net Income TTM ($MM) is 0.00
Nanobiotix S.A. ( NBTX ) Operating Income TTM ($MM) is 0.00
Nanobiotix S.A. ( NBTX ) Owners' Earnings Annual ($MM) is 0.00
Nanobiotix S.A. ( NBTX ) Current Price to Owners' Earnings ratio is 0.00
Nanobiotix S.A. ( NBTX ) EBITDA TTM ($MM) is 0.00
Nanobiotix S.A. ( NBTX ) EBITDA Margin is 0.00%
Capital Allocation:
Nanobiotix S.A. ( NBTX ) has paid 0.00 dividends per share and bought back -0.0018859999999989 million shares in the past 12 months
Nanobiotix S.A. ( NBTX ) has increased its debt by 7.940377 million USD in the last 12 months
Capital Structure:
Nanobiotix S.A. ( NBTX ) Interest-bearing Debt ($MM) as of last quarter is 69
Nanobiotix S.A. ( NBTX ) Annual Working Capital Investments ($MM) are -6
Nanobiotix S.A. ( NBTX ) Book Value ($MM) as of last quarter is -59
Nanobiotix S.A. ( NBTX ) Debt/Capital as of last quarter is -119%
Other Balance Sheet Stats:
Nanobiotix S.A. ( NBTX ) has 23 million in cash on hand as of last quarter
Nanobiotix S.A. ( NBTX ) has 54 million of liabilities due within 12 months, and long term debt 52 as of last quarter
Nanobiotix S.A. ( NBTX ) has 34 common shares outstanding as of last quarter
Nanobiotix S.A. ( NBTX ) has 0 million USD of preferred stock value
Academic Scores:
Nanobiotix S.A. ( NBTX ) Altman Z-Score is -0.18 as of last quarter
Nanobiotix S.A. ( NBTX ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
Nanobiotix S.A. ( NBTX ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Nanobiotix S.A. ( NBTX ) for the amount of $ on
0.00% of Nanobiotix S.A. ( NBTX ) is held by insiders, and 19.36% is held by institutions
Nanobiotix S.A. ( NBTX ) went public on 2020-12-11
Other Nanobiotix S.A. ( NBTX ) financial metrics:
FCF:-39.28
Unlevered Free Cash Flow:-33.31
EPS:0.00
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:0.00
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Nanobiotix S.A. ( NBTX ) :
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.